Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toujeo vs Lantus in Type 1 Diabetes (PDY12777)
NCT01658579Phase 2Completed
- Sponsor
- Sanofi
- Start
- Aug 2012
- Primary completion
- May 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of insulin glargine in type 1 diabetes mellitus (T1D) (4 arms), sponsored by Sanofi. Primary endpoint: Percentage of Time in Target Plasma Glucose Range (4.4-7.8 mmol/L [80-140 mg/dL]) at 16 weeks. Started Aug 2012; status: completed.
02
Drugs
insulin glargine
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT01658579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01658579.